Georgetown University home page Search: Full text search Site Index: Find a web site by name or keyword Site Map: Overview of main pages Directory: Find a person; contact us About this site: Copyright, disclaimer, policies, terms of use Georgetown University home page Home page for prospective students Home page for current students Home page for alumni and alumnae Home page for family and friends Home page for faculty and staff Georgetown University Search: Full text search Site Index: Find a web site by name or keyword Site Map: Overview of main pages Directory: Find a person; contact us About this site: Copyright, disclaimer, policies, terms of use
Navigation bar Navigation bar
spacer spacer spacer spacer
border
spacer spacer spacer
border
spacer spacer

FOR IMMEDIATE RELEASE: May 15, 2008


CONTACT:

Karen Mallet
414-312-7085
km463@georgetown.edu


Study Suggests Blood Test Can Help Lead To Improved Treatment Outcomes for Breast Cancer Patients

Georgetown researchers say circulating tumor cells are a reliable predictor of treatment response in metastatic breast cancer; Treatment change could occur sooner


Washington, DC -- With the goal of tailoring cancer treatment for each individual, researchers at Georgetown’s Lombardi Comprehensive Cancer Center will present a study that suggests a simple blood test can help doctors more reliably assess treatment efficacy for patients with metastatic breast cancer.  The study’s abstract was released online today at asco.org in advance of the American Society of Clinical Oncology annual meeting. 

“It can take several weeks and sometimes months to determine if a particular cancer treatment is working because it can take that long to observe any significant radiographic changes in tumor size or appearance,” says Minetta Liu, M.D., of Georgetown’s Lombardi Comprehensive Cancer Center.  “Right now, we have to rely on radiology studies such as CT scans, ultrasound, and the like to determine whether or not there is disease progression.  With this new blood test, we have another reliable tool that may allow us to determine much sooner if a therapy is ineffective so that we can change therapy earlier and potentially make more significant improvements in survival.”

Using the FDA-approved CellSearch™ technology, researchers measured the number of circulating tumor cells (CTC) in blood collected from women with metastatic breast cancer.  About one tablespoon of blood was collected every three to four weeks.  The number of CTCs was correlated with disease response or progression as determined by standard radiology studies performed every 9-12 weeks.  The women in the study received various treatments including chemotherapy, endocrine therapy, and combination therapy with a biologic agent. 

A CTC count of five was used as the threshold, based on previous studies.  There was a highly significant difference in the distribution of progression between two groups of patients defined by their CTC result. Seventy-one percent of patients who had a CTC greater than or equal to five had disease progression, and 66 percent of patients with a CTC count of less than five did not. 

“A CTC count of five or greater at the time of restaging was associated with a 5.32 fold increase in a patient’s chance of having disease progression compared to CTC counts of less than five,” explains Liu.  “CTC assessments should be used as a surrogate marker for treatment efficacy and disease responsiveness. Changes in CTC results from less than five to greater than or equal to five over time may herald disease progression.” 

Liu adds that the CTC assay is a more reliable means of assessing treatment response than the traditional tumor markers currently in use.

“We have a follow-up study underway that evaluates CTC results within the framework of a randomized clinical trial to eliminate potential variability from the treatment administered, ”says Liu, the national principal investigator of the new trial.  Liu and her colleagues believe a study with the same therapies would offer even stronger evidence for routine use of CTC in patients with metastatic breast cancer. 

“We have many treatment options for advanced breast cancer.  The key is to find the most effective therapy for each patient. It shouldn’t take months to figure that out,” she concludes.

The study was funded by Veridex, LLC, makers of CellSearch.  Liu reports receiving limited compensation for research-related speaking engagements on behalf of Veridex.

The complete data will be presented during the poster discussion of this study at the annual meeting place in Chicago May 30-June 3.

About Lombardi Comprehensive Cancer Center
The Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center and Georgetown University Hospital, seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic and clinical research, patient care, community education and outreach, and the training of cancer specialists of the future. Lombardi is one of only 41 comprehensive cancer centers in the nation, as designated by the National Cancer Institute, and the only one in the Washington, DC, area. For more information, go to http://lombardi.georgetown.edu.

About Georgetown University Medical Center
Georgetown University Medical Center
is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through our partnership with MedStar Health). Our mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing and Health Studies, both nationally ranked, the world-renowned Lombardi Comprehensive Cancer Center and the Biomedical Graduate Research Organization (BGRO), home to 60 percent of the university’s sponsored research funding.

###

 




spacer spacer
Navigation bar Navigation bar